About | Free Trial

Last Update

2009-02-17T00:00:00.000Z

This profile was last updated on // .

Is this you? Claim your profile.

Wrong Debbie Yu?

Dr. Debbie Yu M.D.

Physician and Managing Director

Bay City Capital LLC

HQ Phone: (415) 676-3830

Bay City Capital LLC

750 Battery Street Suite 400

San Francisco, California 94111

United States

Company Description

Bay City Capital also serves as the Investment Advisor to the $111 million North American Nutrition and Agriculture Fund (NANAF). Formed in 1999, NANAF, along with its European and Australian sister funds, operates under the umbrella of the Gilde Food & A ... more

Find other employees at this company (53)

Background Information

Affiliations

Investment Advisor
ChinaBio LLC

Board Member
ASLAN Pharmaceuticals Pte Ltd

Board Member
Xenogen Corporation

Member
Forum for Women Entrepreneurs

Education

A.B. with high honors
Molecular Biology
Princeton University

B.A. with high honors
Molecular Biology
Princeton

BA
Molecular Biology
Princeton University

M.D.

Harvard University

MD

Harvard Medical School

Web References (166 Total References)


WuXi PharmaTech - Press Releases

ir.wuxipharmatech.com, $reference.date [cached]

SHANGHAI, China, July 10 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that it has appointed Dr. Debra Yu as the Vice President of Strategy.

Prior to joining WuXi PharmaTech, Dr. Yu worked at Pfizer Inc., where she co-led Pfizer's venture capital group and was instrumental in working in diverse areas such as diagnostics, asset monetization and creative finance structures and Pfizer's innovation agenda. Earlier she was a General Partner at Delphi Ventures and a Managing Director at Bay City Capital, two leading Bay area venture firms focused on the life sciences. In addition, Dr. Yu has held senior positions at many leading companies and organizations like McKinsey & Co., the U.S. Food and Drug Administration (FDA), the Wilkerson Group, Morgan Stanley & Co., Genentech Inc. and the Permanente Company. She has stewarded more than 25 companies through venture capital, and sat on the board of eight and stepped in as Chief Executive Officer of one.
Dr. Yu's responsibilities in her new role include bringing constructive leadership and stewardship to the company's strategic planning and initiatives. Dr. Yu will report directly to Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.
...
"I am very pleased to welcome Debra on board to further increase the depth of our senior management," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.
...
"With 19 years of experiences in venture capital and life sciences, Debra will provide strategic guidance as we continue building a global drug and medical device R&D service platform through organic growth, partnership and M&A."
Dr. Yu received her BA in Molecular Biology from Princeton University, New Jersey in 1986 and her MD from Harvard Medical School, Massachusetts in 1992.


WuXi AppTec: Investor Relations - Press Releases

ir.wuxipharmatech.com, $reference.date [cached]

SHANGHAI, China, July 10 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that it has appointed Dr. Debra Yu as the Vice President of Strategy.

Prior to joining WuXi PharmaTech, Dr. Yu worked at Pfizer Inc., where she co-led Pfizer's venture capital group and was instrumental in working in diverse areas such as diagnostics, asset monetization and creative finance structures and Pfizer's innovation agenda. Earlier she was a General Partner at Delphi Ventures and a Managing Director at Bay City Capital, two leading Bay area venture firms focused on the life sciences. In addition, Dr. Yu has held senior positions at many leading companies and organizations like McKinsey & Co., the U.S. Food and Drug Administration (FDA), the Wilkerson Group, Morgan Stanley & Co., Genentech Inc. and the Permanente Company. She has stewarded more than 25 companies through venture capital, and sat on the board of eight and stepped in as Chief Executive Officer of one.
Dr. Yu's responsibilities in her new role include bringing constructive leadership and stewardship to the company's strategic planning and initiatives. Dr. Yu will report directly to Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.
...
"I am very pleased to welcome Debra on board to further increase the depth of our senior management," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.
...
"With 19 years of experiences in venture capital and life sciences, Debra will provide strategic guidance as we continue building a global drug and medical device R&D service platform through organic growth, partnership and M&A."
Dr. Yu received her BA in Molecular Biology from Princeton University, New Jersey in 1986 and her MD from Harvard Medical School, Massachusetts in 1992.


WuXi PharmaTech - Press Releases

ir.wuxiapptec.com, $reference.date [cached]

SHANGHAI, China, July 10 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that it has appointed Dr. Debra Yu as the Vice President of Strategy.

Prior to joining WuXi PharmaTech, Dr. Yu worked at Pfizer Inc., where she co-led Pfizer's venture capital group and was instrumental in working in diverse areas such as diagnostics, asset monetization and creative finance structures and Pfizer's innovation agenda. Earlier she was a General Partner at Delphi Ventures and a Managing Director at Bay City Capital, two leading Bay area venture firms focused on the life sciences. In addition, Dr. Yu has held senior positions at many leading companies and organizations like McKinsey & Co., the U.S. Food and Drug Administration (FDA), the Wilkerson Group, Morgan Stanley & Co., Genentech Inc. and the Permanente Company. She has stewarded more than 25 companies through venture capital, and sat on the board of eight and stepped in as Chief Executive Officer of one.
Dr. Yu's responsibilities in her new role include bringing constructive leadership and stewardship to the company's strategic planning and initiatives. Dr. Yu will report directly to Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.
...
"I am very pleased to welcome Debra on board to further increase the depth of our senior management," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.
...
"With 19 years of experiences in venture capital and life sciences, Debra will provide strategic guidance as we continue building a global drug and medical device R&D service platform through organic growth, partnership and M&A."
Dr. Yu received her BA in Molecular Biology from Princeton University, New Jersey in 1986 and her MD from Harvard Medical School, Massachusetts in 1992.


WuXi AppTec: Investor Relations - Press Releases

ir.wuxiapptec.com, $reference.date [cached]

SHANGHAI, China, July 10 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that it has appointed Dr. Debra Yu as the Vice President of Strategy.

Prior to joining WuXi PharmaTech, Dr. Yu worked at Pfizer Inc., where she co-led Pfizer's venture capital group and was instrumental in working in diverse areas such as diagnostics, asset monetization and creative finance structures and Pfizer's innovation agenda. Earlier she was a General Partner at Delphi Ventures and a Managing Director at Bay City Capital, two leading Bay area venture firms focused on the life sciences. In addition, Dr. Yu has held senior positions at many leading companies and organizations like McKinsey & Co., the U.S. Food and Drug Administration (FDA), the Wilkerson Group, Morgan Stanley & Co., Genentech Inc. and the Permanente Company. She has stewarded more than 25 companies through venture capital, and sat on the board of eight and stepped in as Chief Executive Officer of one.
Dr. Yu's responsibilities in her new role include bringing constructive leadership and stewardship to the company's strategic planning and initiatives. Dr. Yu will report directly to Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.
...
"I am very pleased to welcome Debra on board to further increase the depth of our senior management," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.
...
"With 19 years of experiences in venture capital and life sciences, Debra will provide strategic guidance as we continue building a global drug and medical device R&D service platform through organic growth, partnership and M&A."
Dr. Yu received her BA in Molecular Biology from Princeton University, New Jersey in 1986 and her MD from Harvard Medical School, Massachusetts in 1992.


WuXi PharmaTech

www.pharmatechs.com, $reference.date [cached]

Debra Yu, M.D. Vice President, Strategy

Dr. Yu received her B.A. with high honors in Molecular Biology from Princeton in 1986 and earned an M.D. from Harvard Medical School in 1992. She has 19 years of experience in venture capital and the life sciences industry. Most recently she co-lead Pfizer's venture capital group in New York. While at Pfizer she was instrumental in work in diverse areas such as diagnostics, asset monetization and creative finance structures and Pfizer's innovation agenda. Previously, she was a General Partner at Delphi Ventures and a Managing Director at Bay City Capital, two leading bay area venture firms focused on the life sciences. Debra also spent four years at Mckinsey in New York and London. She has held positions at the FDA, The Wilkerson Group, Morgan Stanley and Genentech. She has stewarded more than 25 companies through venture capital, sat on the board of 8 and stepped in as CEO of one. Debra also served as a Director of the Permanente Company, part of Kaiser Permanente and helped build its corporate venture efforts.
...
Debra Yu, M.D. Vice President, Strategy
Vice President, Domestic Marketing

Similar Profiles

Other People with this Name (51,142)

Other people with the name Yu

Frank Yu
AppTec Laboratory Services , Inc.

Janet Yu
Silicon Valley Accountancy Corporation

Jeff Yu
Truck Loads

Lotus Yu

Joon Yu
Palo Alto Investors LLC

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory